Voyager Therapeutics, Inc. Common Stock
VYGRVoyager Therapeutics, Inc. (VYGR) is a biotechnology company focused on developing gene therapies for neurological diseases. Utilizing its proprietary AAV (adeno-associated virus) platform, Voyager aims to deliver potentially one-time treatments for conditions such as Parkinson's disease, Rett syndrome, and other neurodegenerative disorders. The company emphasizes innovative approaches to develop therapies that can modify disease progression and improve patient outcomes.
Company News
Johnson & Johnson discontinued its Phase 2b AuTonomy study of posdinemab after the drug failed to show statistical significance in slowing clinical decline for early Alzheimer's disease patients.
Voyager Therapeutics expanded its Alzheimer's disease franchise by introducing a new gene therapy program targeting APOE, complementing existing tau and amyloid assets. The program aims to reduce APOE4 variant expression while delivering the protective APOE2 variant using an innovative IV-delivered TRACER capsid.
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 54.55% and 88.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Small-caps had a great end to 2023, but hedge funds may only be covering their shorts. Beware says our call of the day.
These biotech companies are seeing a spike in revenue growth.
